Dilt-XR

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dilt-XR

Quick Facts

Property Description
Active ingredient Diltiazem hydrochloride
Form Extended-release capsule
Pharmacological Class Calcium Channel Blocker (Non-DHP)
General Purpose Managing blood pressure and heart rhythm
Origin Synthetic Benzothiazepine derivative

What Type of Medicine is Dilt-XR?

Dilt-XR is a prescription-only medicinal entity whose active ingredient is Diltiazem hydrochloride, a compound synthesized as a Benzothiazepine derivative. It is classified as a Calcium Channel Blocker (CCB), placing it within the broader antihypertensive agent and anti-anginal agent pharmacological class. The Diltiazem substance is further specified as a Non-dihydropyridine CCB, a distinction clinically recognized in comprehensive reviews of cardiovascular agents. This classification means the drug has significant effects on both the peripheral blood vessels and the heart's electrical system.

Understanding the Extended-Release Form

The Dilt-XR formulation is a single-ingredient product presented in an extended-release capsule, which is an oral dosage form designed for once-a-day dosage. The -XR suffix specifically denotes this controlled-release characteristic, a key manufacturing differentiation designed to ensure the slow, sustained release of Diltiazem hydrochloride. This design is engineered to maintain a steady, therapeutic concentration over a full 24-hour cycle, which is essential for sustained therapeutic action in managing chronic cardiovascular system conditions.

General Purpose of Diltiazem

The fundamental purpose of Diltiazem is to reduce physical strain and workload on the heart. Its mechanism involves acting as a calcium antagonist to limit the influx of calcium ions into heart and vascular smooth muscle cells, which facilitates the relaxation of blood vessels and decreases peripheral vascular resistance. This action, coupled with its ability to influence the heart’s intrinsic electrical conduction, makes the drug principally applicable as an antihypertensive agent and an anti-anginal agent. The labeling for Diltiazem supports its utility in managing conditions associated with high blood pressure and chronic stable angina.

What side effects are possible with Dilt-XR?

Possible Side Effects and Safety Information

The official safety documentation for Dilt-XR is organized around cardiovascular risks, potential serious systemic effects, and common adverse reactions observed in clinical trials.

Cardiovascular and Serious Reactions

This medicine is contraindicated in patients with specific pre-existing conditions, including Sick Sinus Syndrome or Second-/Third-Degree Atrioventricular (AV) Block unless a functioning ventricular pacemaker is present, Severe Hypotension (systolic pressure <90 mmHg), and Acute Myocardial Infarction with Pulmonary Congestion.

Serious, but less frequent, adverse reactions that have been documented include:

  • Acute Hepatic Injury (liver damage), which is generally reversible upon discontinuation of the medicine.
  • Severe Skin Reactions, such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Exfoliative Dermatitis.
  • Worsening of Heart Failure and marked Bradycardia (abnormally slow heart rate) or higher-degree AV Block.

Common Adverse Reactions

The most frequently reported adverse reactions, typically seen in 1% to 10% of patients across clinical trials (classified as Common), are generally less severe and often relate to the medicine's vasodilatory effects. These include edema (swelling, particularly lower limb), headache, dizziness, and constipation.

Population and Monitoring Notes

Caution is advised when administering Dilt-XR to the elderly and patients with renal or hepatic impairment, as altered drug clearance may increase the risk of adverse effects. Concomitant use with other agents that depress cardiac contractility or conduction, such as beta-blockers or digoxin, may increase the risk of bradycardia and AV Block, and requires close monitoring.

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected overdose of Dilt-XR requires immediate medical attention. Contacting emergency services immediately is mandatory, as this situation carries the potential for severe and life-threatening outcomes.

Documented Clinical Manifestations

Official regulatory documents detail the expected physiological effects of an overdose, which include significant severe hypotension (low blood pressure) and profound bradycardia (abnormally slow heart rate). Patients may also exhibit various degrees of Atrioventricular (AV) block or signs indicative of heart failure. The potential for escalation to critical severe outcomes, such as cardiogenic shock, asystole (cardiac arrest), and respiratory depression, underscores the necessity of urgent medical intervention.

Required Emergency Procedures and Monitoring

Upon suspected overdose, management must occur in a setting capable of providing continuous intensive care monitoring. A prolonged observation period—frequently documented as 48 hours or longer—is required due to the extended-release nature of the capsule, which carries a risk of delayed peak effects or relapse. Management focuses on symptomatic and supportive treatment, as no specific antidote is known. Officially described supportive measures include the administration of intravenous calcium, the use of vasopressors to treat sustained hypotension, and interventions like atropine or temporary cardiac pacing for managing severe conduction disturbances.

Therapeutic Uses of Dilt-XR

What Dilt-XR Treats: Main Uses and Benefits

Dilt-XR is a prescription therapy used for the long-term management of several chronic cardiovascular conditions. It is generally used to support sustained management of symptomatic domains, focusing on easing the overall symptom burden and assisting with functional stability. This medication is applied across domains where additional symptomatic support is needed.


The primary therapeutic use is in Antihypertensive Therapy to support the sustained lowering of elevated systemic pressure, as well as in Anti-anginal Therapy for managing symptoms of chronic stable angina and vasospastic angina. It is also considered relevant for easing symptoms associated with excessively rapid heart rate in certain supraventricular arrhythmias. This therapy is commonly used to help with reducing the risk of serious cardiovascular events associated with uncontrolled high blood pressure.

Quick Fact: Therapeutic Support

Symptom Domain Key Benefit
Elevated Systemic Pressure Supports the sustained lowering of elevated pressure
Ischemic Chest Discomfort Contributes to easing the overall symptom load
Rapid Heart Rhythm Assists with stability during routine function

By assisting with the stabilization of the heart rate and addressing symptom clusters related to ischemic chest discomfort, Dilt-XR provides supportive relief that contributes to improved day-to-day comfort and assisting with stability during routine function during periods of heightened symptoms.

Regulatory References

  1. DailyMed NLM Drug Labeling Information

Eligibility and Restrictions for Use

This section summarizes the official eligibility and non-eligibility information for Dilt-XR (diltiazem extended-release), based on government regulatory documentation. Eligibility is determined by the absence of specific heart conditions and other restrictions.

Populations for Whom Use is Prohibited (Contraindicated)

Use of Dilt-XR is formally contraindicated in patients with the following severe conditions, unless otherwise noted:

  • Cardiac Conduction Block: Sick sinus syndrome or second- or third-degree atrioventricular (AV) block, except in the presence of a functioning ventricular pacemaker.
  • Accessory Bypass Tract: Atrial fibrillation or flutter associated with an accessory bypass tract (e.g., Wolff-Parkinson-White [WPW] syndrome).
  • Hemodynamic Instability: Severe hypotension (systolic blood pressure typically below 90 mm Hg), cardiogenic shock, or acute myocardial infarction with pulmonary congestion.
  • Hypersensitivity: Known allergy or hypersensitivity to diltiazem hydrochloride or any component of the formulation.

Other Eligibility Considerations

Population/Condition Eligibility Status (Official)
Pediatric Use Safety and efficacy have not been established (use not recommended in children).
Pregnancy/Lactation Contraindicated in some jurisdictions; use should be determined by a healthcare provider after weighing risks and benefits, as the drug passes into breast milk.
Impaired Function Use with caution in patients with impaired renal or hepatic function; close monitoring may be required.
Geriatric Use Use with caution due to potential age-related decrease in organ function, often requiring lower starting doses and careful titration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Dilt-XR (Diltiazem) is defined by its effects as a moderate inhibitor of the CYP3A4 enzyme and a P-glycoprotein (P-gp) transporter inhibitor, alongside its additive effects on the heart's function. These properties establish specific regulatory constraints for co-administration.

Contraindicated Combinations

Certain combinations are strictly contraindicated based on official regulatory labeling. This includes co-administration with Ivabradine due to an additive heart rate lowering effect and with Dantrolene (infusion) due to the risk of cardiovascular collapse. Substances highly sensitive to CYP3A4 inhibition, such as Pimozide and Lonafarnib, are also prohibited due to the risk of increased plasma concentrations leading to toxicity.

Pharmacokinetic and Pharmacodynamic Interactions

The inhibition of CYP3A4 and P-gp formally results in increased exposure (plasma concentrations) of numerous co-administered medicinal products, including certain statins (e.g., Simvastatin), immunosuppressants (e.g., Cyclosporine), and Digoxin. This requires careful monitoring. Furthermore, Diltiazem's antiarrhythmic properties lead to additive pharmacodynamic effects when combined with other cardiac depressants, such as beta-blockers and other antiarrhythmic agents, increasing the documented risk of bradycardia and AV block.

Non-Medicinal Substance Restrictions

Official labeling documents that the consumption of alcoholic beverages must be avoided with the extended-release formulation due to a documented increase in the rate and extent of Diltiazem exposure. Similarly, Grapefruit juice may significantly increase Diltiazem blood levels.

Mechanism of Action

The mechanism of Dilt-XR is defined by the unique way its active ingredient, Diltiazem, interacts with the cardiovascular system as a non-dihydropyridine calcium channel blocker. It primarily acts by antagonizing the L-type Voltage-Dependent Calcium Channels ( L-VDCCs) found in three key areas: the heart's conduction system, the heart muscle, and the blood vessel walls. This targeted molecular action initiates simultaneous physiological cascades that collectively determine the full range of its pharmacodynamic consequences.


Regulating Electrical Impulse Conduction

This domain focuses on Diltiazem's action on the heart’s electrical system, specifically the SA and AV nodes. By blocking L-VDCCs in these areas, the drug slows the speed of electrical impulse transmission (Negative Dromotropy) and reduces the intrinsic firing rate (Negative Chronotropy). This effect is often use-dependent, meaning the blockade is more pronounced at higher frequencies of cellular depolarization.


Modulating Myocardial Contractile Force

This mechanistic domain centers on the heart muscle's ability to contract. By limiting the influx of calcium ions into the working myocardial cells, Diltiazem interferes with the excitation-contraction coupling pathway. This results in a reduced force of contraction (Negative Inotropy), which causes a corresponding reduction in myocardial metabolic oxygen consumption.


Causing Vascular Smooth Muscle Relaxation

In this domain, Diltiazem's blockade of L-VDCCs on the walls of peripheral and coronary arteries inhibits the calcium-dependent mechanisms responsible for muscle contraction. The resulting relaxation of vascular smooth muscle causes Vasodilation, which widens the vessel diameter and reduces systemic vascular resistance.

Dosage and Administration Information

How to Use Dilt-XR

Dilt-XR, the extended-release formulation of Diltiazem hydrochloride, is administered orally and is designed for once-daily use, a frequency related to its controlled-release mechanism. The purpose of this formulation is to maintain a sustained concentration of the active ingredient over a 24-hour period. To preserve this function, the capsule or tablet must be swallowed whole; it is recommended that the medication not be crushed or chewed.


Standard Administration and Dosing

The standard adult starting dose generally ranges from 180 mg to 240 mg once daily, depending on the specific product and clinical application. There is an established maximum recommended dose of 540 mg once per day. Dose adjustments, or titration, are a deliberate process: changes should only be implemented at intervals of 7 to 14 days to allow the current dosage to achieve its full therapeutic effect before further modification.

Administration may be taken without regard to food for most products, although certain extended-release capsule brands are specifically recommended to be taken on an empty stomach.


Specific Population Rules

A cautious approach is used for certain patient groups. A lower starting dose of 120 mg once daily is utilized for older adults and individuals with hepatic (liver) or renal (kidney) impairment, with subsequent dosage increases requiring careful monitoring. Furthermore, the medication is not recommended for pediatric use, as its safety and effectiveness in children have not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dilt-XR

The clinical evaluation of Dilt-XR is based on official research evidence, including data from controlled trials and observational studies, which research explores its use in specific cardiovascular contexts. This overview describes what the research has examined and what the findings, according to official sources, suggest about the structure of the evidence, while also highlighting key limitations and areas where data is still emerging.


Research Evidence for Managing High Blood Pressure

Studies have explored the use of extended-release diltiazem for essential hypertension (elevated blood pressure). The research primarily consists of short-term, randomized, double-blind, placebo-controlled trials (RCTs) conducted in adult populations. These trials were applied in research exploring how blood pressure values change over defined time intervals. Studies reported measurements of changes in blood pressure values measured during the study period, aligning with the formulation's design.

Long-term observational studies, which tracked the broader drug class, research examined the association between blood pressure changes observed over time and long-term endpoints, such as the overall risk of major cardiovascular events. Evidence for long-term cardiovascular event outcomes is largely derived from data for the drug class and is inferred from the consistent findings on blood pressure changes observed in controlled trials.


Research Evidence for Managing Chronic Chest Discomfort (Angina)

Dilt-XR was also evaluated in studies focusing on conditions characterized by episodic changes in outcomes related to physical discomfort, specifically chronic stable angina and vasospastic angina. Research in this area includes RCTs that monitored functional outcomes, primarily by measuring exercise tolerance and tracking the weekly frequency of anginal episodes.

A significant point of uncertainty is the duration of the follow-up periods in many of the core trials for angina, which were typically short- to intermediate-term (e.g., 4 to 12 weeks). This means that long-term effects are not fully established regarding the durability of the anti-anginal effect or the medication's impact on underlying disease progression or mortality over several years. Data for certain groups, such as pediatric populations, remain insufficient, and the evidence quality varies across studies focusing on severe, complex comorbid conditions.

Key Studies & References DailyMed Labeling for Diltiazem Extended-Release Capsules (Dilt-XR Equivalent)

Frequently Asked Questions (FAQ)

Common questions about Dilt-XR (FAQ)


Q: How quickly should I expect Dilt-XR to start controlling my blood pressure?

Studies and official information indicate that while blood levels of the medicine are detectable within a few hours, the maximum blood pressure-lowering effect is typically achieved after about two weeks (14 days) of continuous, chronic use. This is why dose adjustments, if needed, are usually only made after this time period to allow the drug to fully reach its sustained therapeutic effect.


Q: Is it normal to feel dizzy or lightheaded when starting Dilt-XR?

Yes, regulatory documents list dizziness and lightheadedness as common side effects reported by patients, particularly when therapy is first initiated. These feelings relate to the drug's effect of lowering blood pressure. The potential for dizziness means patients may need to exercise caution. If this persists, it is important to check with a healthcare provider.


Q: Can taking Dilt-XR make me tired during the day?

According to official product information, fatigue (feeling unusually tired or weak) is a reported adverse reaction. Other related symptoms, such as asthenia (a lack of energy), may also be reported. Concerns about persistent tiredness or fatigue can be reviewed with a healthcare provider.


Q: What should I do if I miss a dose of Dilt-XR?

Patient information outlines the standard procedure for a missed dose, which typically involves taking the dose when remembered unless it is nearly time for the next dose. It is generally cautioned that a double or extra dose should not be taken to compensate for a missed dose. Specific guidance for handling a missed dose should be obtained from the dispensing pharmacy or healthcare provider.


Q: What is the purpose of the insoluble shell sometimes seen in stool after taking Dilt-XR?

The extended-release version of this medicine is often contained within an insoluble shell designed to slowly release the active ingredient over 24 hours. Once the medicine is released, the empty shell may pass intact in the stool. This phenomenon is documented in official product information and is generally expected with this type of extended-release design.


Q: Does Dilt-XR cause weight gain?

General weight gain is not explicitly listed as a common side effect in regulatory documents. However, a less common but serious risk associated with the drug is the worsening of heart failure, which can include signs such as rapid weight gain or sudden swelling. Unexpected or rapid weight changes are important to review with a healthcare professional.


Q: Is it safe to take Dilt-XR with acid reflux medication?

Official regulatory documents do not list common acid reflux medicines, such as H2 antagonists or PPIs, as major interacting drugs. Since Diltiazem is metabolized by the CYP3A4 enzyme in the liver, it is important that all potential interactions, including those with over-the-counter products, are reviewed with a healthcare provider.


Q: Does Dilt-XR interact with common over-the-counter pain relievers like ibuprofen?

Authoritative patient guides suggest consulting a healthcare provider before using over-the-counter products that could potentially affect blood pressure. This includes non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, which may raise blood pressure in some individuals. It is important that all supplements are reviewed with a healthcare provider.


Q: Can younger adults or teens be prescribed Dilt-XR?

Official labeling states that the safety and effectiveness of Diltiazem extended-release in pediatric patients (children) has not been established. The drug is generally not recommended for use in this younger population.


Q: Does Dilt-XR interact with herbal supplements like St. John's Wort?

Yes, official regulatory warnings and patient materials specifically advise caution regarding certain herbal supplements. Products containing St. John's Wort are highlighted as they may interfere with the metabolism of diltiazem and affect how the medicine works in the body.


Q: Why do some people use Dilt-XR for chest pain (angina)?

Dilt-XR is formally indicated for the management of angina (chest pain) because of its mechanism of action. The drug works by relaxing vascular smooth muscle in the heart's arteries, which increases blood flow and oxygen delivery to the heart muscle. This action helps reduce the occurrence and severity of chest discomfort.


Q: Can I switch from another diltiazem product to Dilt-XR without issues?

According to official administration guidelines, patients on other formulations of diltiazem can generally be switched to Dilt-XR at an equivalent total daily dose. While a switch can be made, subsequent adjustments based on the individual's clinical response may be necessary.


Q: Does Dilt-XR affect cholesterol levels?

Dilt-XR is not indicated for treating cholesterol. However, regulatory documents warn that diltiazem can increase the blood levels of certain cholesterol-lowering drugs, specifically some statins like simvastatin. If taken together, monitoring and potential adjustment of the statin dosage by a healthcare provider may be necessary.


Q: Are there generic versions of Dilt-XR available?

Yes, the active ingredient, Diltiazem Hydrochloride extended-release, is available from multiple manufacturers as a generic drug product.


Q: How often do patients typically need their blood tests checked while on Dilt-XR?

Official labeling does not specify a general schedule for blood tests. However, it does require healthcare providers to monitor for signs of liver damage by checking liver enzymes periodically, as acute hepatic injury is a reported, though less common, adverse reaction.


Q: Can Dilt-XR affect sleep or cause insomnia?

Trouble sleeping or insomnia is listed as a less common side effect in some authoritative side effects profiles for diltiazem products. Persistent changes in sleep patterns are important to discuss with a healthcare provider.


Q: Does Dilt-XR have a warning about driving or operating machinery?

Yes, official patient guides advise caution with activities like driving or operating machinery until it is known how the medication affects the individual, given the potential for dizziness or lightheadedness.


Q: Will I need to take Dilt-XR for the rest of my life for blood pressure control?

Dilt-XR is indicated for the chronic treatment of conditions like high blood pressure and angina. Successful management of these long-term cardiovascular conditions typically requires continuous therapy, often for extended periods.


Q: Is a persistent cough a common side effect of Dilt-XR?

Cough is listed as a reported adverse reaction based on clinical trial data for diltiazem extended-release. Any concerns about a persistent cough can be brought to the attention of a healthcare professional.


Q: What is the evidence that Dilt-XR can prevent heart attacks?

Official clinical studies show that Dilt-XR is effective at lowering high blood pressure. By lowering blood pressure, the drug helps reduce the overall risk of major fatal and nonfatal cardiovascular events, which includes events like strokes and myocardial infarctions (heart attacks). Efficacy is often inferred from its ability to maintain healthy blood pressure levels.


Q: Are there specific supplements that should be avoided while on Dilt-XR?

In addition to St. John's Wort and Grapefruit juice, some patient guides suggest avoiding Hawthorn and certain multivitamin with mineral products, as they may interact with the effects of diltiazem. It is important that all supplements are reviewed with a healthcare provider.


Q: Does Dilt-XR have to be stored in a special way?

The product must be stored correctly to maintain its integrity. Regulatory documents specify that it should be kept at Controlled Room Temperature (approximately 25 C or 77 F) and protected from excessive humidity. It should also be stored in the provided tight, light-resistant container.


Q: What is the half-life of Dilt-XR?

The apparent elimination half-life for the extended-release, once-daily formulation of Diltiazem is typically reported to be between 5 to 8 hours. The extended-release formulation is designed to maintain consistent blood levels despite this relatively short half-life.


Q: Why is my blood pressure still high even though I'm taking Dilt-XR?

Official information indicates that the full therapeutic effect of Dilt-XR can take up to 14 days to be realized. If blood pressure remains high after this period, adjustment of the dosage or use in combination with another medication may be considered by a healthcare provider.

How should Dilt-XR be stored and disposed of?

Storage and Disposal Conditions for Dilt-XR

Dilt-XR must be stored at Controlled Room Temperature, which is officially defined as 25 C (77 F) . The regulatory labeling permits temperature excursions between 15 C and 30 C (59 F and 86 F).

Requirement Details (Official Labeling)
Temperature Range 15 C to 30 C (59 F to 86 F)
Protection Avoid excessive humidity and store in a light-resistant, tight container
Container Must have a child-resistant closure
Child Safety Keep out of reach of children (Mandatory warning)

Official documents require the medicine to be protected from both high moisture and light to maintain the integrity of the extended-release formulation. The regulatory labeling does not contain explicit household disposal instructions for unused or expired product, meaning disposal should follow local and national drug take-back or disposal programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dilt-XR found in:

A-Z Index: